Kelyniam Global Announces Q1 2025 Financial Results and Strategic Partnership
Kelyniam Global (OTC: KLYG), a custom cranial implant manufacturer, reported challenging Q1 2025 results with revenue declining 34.7% to $624,910 from $957,447 in Q1 2024. The company posted an operating loss of $(140,556) compared to a profit of $123,599 in the prior year. To address these challenges, Kelyniam appointed Alex Rivero as National Sales Director and plans to add 10 new distributors in 2025.
The company announced a significant three-year distribution agreement with Osteopore Ltd. to distribute their bioresorbable products in the U.S., including Osteostrip®, Osteoplug®, and Osteomesh®. This partnership, along with Finceramica, positions Kelyniam as a leader in regenerative medicine for cranial surgery while maintaining their commitment to 24-48 hour custom implant delivery.
Kelyniam Global (OTC: KLYG), un produttore di impianti cranici su misura, ha riportato risultati difficili nel primo trimestre del 2025 con un calo del fatturato del 34,7%, sceso a 624.910 $ rispetto ai 957.447 $ del primo trimestre 2024. L'azienda ha registrato una perdita operativa di (140.556 $) rispetto a un utile di 123.599 $ dell'anno precedente. Per affrontare queste difficoltà, Kelyniam ha nominato Alex Rivero direttore nazionale delle vendite e prevede di aggiungere 10 nuovi distributori nel 2025.
L'azienda ha annunciato un importante accordo di distribuzione triennale con Osteopore Ltd. per la distribuzione dei loro prodotti bioassorbibili negli Stati Uniti, inclusi Osteostrip®, Osteoplug® e Osteomesh®. Questa partnership, insieme a Finceramica, posiziona Kelyniam come leader nella medicina rigenerativa per la chirurgia cranica, mantenendo l'impegno nella consegna di impianti personalizzati entro 24-48 ore.
Kelyniam Global (OTC: KLYG), un fabricante de implantes craneales personalizados, reportó resultados desafiantes en el primer trimestre de 2025 con ingresos que disminuyeron un 34.7%, alcanzando $624,910 desde $957,447 en el primer trimestre de 2024. La compañía registró una pérdida operativa de $(140,556) en comparación con una ganancia de $123,599 del año anterior. Para enfrentar estos desafíos, Kelyniam nombró a Alex Rivero como Director Nacional de Ventas y planea añadir 10 nuevos distribuidores en 2025.
La empresa anunció un importante acuerdo de distribución de tres años con Osteopore Ltd. para distribuir sus productos bioabsorbibles en EE.UU., incluyendo Osteostrip®, Osteoplug® y Osteomesh®. Esta asociación, junto con Finceramica, posiciona a Kelyniam como líder en medicina regenerativa para cirugía craneal, manteniendo su compromiso con la entrega de implantes personalizados en 24-48 horas.
Kelyniam Global (OTC: KLYG)는 맞춤형 두개골 임플란트 제조업체로, 2025년 1분기 실적이 어려움을 겪으며 매출이 2024년 1분기 957,447달러에서 34.7% 감소한 624,910달러를 기록했습니다. 회사는 영업손실 (140,556달러)을 기록했으며, 이는 전년도의 123,599달러 이익과 비교됩니다. 이러한 문제를 해결하기 위해 Kelyniam은 알렉스 리베로를 전국 영업 이사로 임명했으며 2025년에 10개의 신규 유통업체를 추가할 계획입니다.
회사는 미국 내에서 Osteostrip®, Osteoplug®, Osteomesh®를 포함한 생체흡수성 제품을 유통하기 위한 Osteopore Ltd.와의 3년 배급 계약을 체결했다고 발표했습니다. 이 파트너십과 Finceramica와의 협력은 Kelyniam을 두개골 수술용 재생 의학 분야의 선두주자로 자리매김하게 하며, 24-48시간 내 맞춤형 임플란트 배송 약속을 유지합니다.
Kelyniam Global (OTC : KLYG), fabricant d'implants crâniens sur mesure, a annoncé des résultats difficiles pour le premier trimestre 2025 avec un chiffre d'affaires en baisse de 34,7 %, atteignant 624 910 $ contre 957 447 $ au premier trimestre 2024. La société a enregistré une perte d'exploitation de (140 556 $) contre un bénéfice de 123 599 $ l'année précédente. Pour relever ces défis, Kelyniam a nommé Alex Rivero directeur national des ventes et prévoit d'ajouter 10 nouveaux distributeurs en 2025.
L'entreprise a annoncé un important accord de distribution triennal avec Osteopore Ltd. pour distribuer leurs produits bio-résorbables aux États-Unis, notamment Osteostrip®, Osteoplug® et Osteomesh®. Ce partenariat, associé à Finceramica, positionne Kelyniam en tant que leader en médecine régénérative pour la chirurgie crânienne, tout en maintenant son engagement à livrer des implants sur mesure sous 24 à 48 heures.
Kelyniam Global (OTC: KLYG), ein Hersteller von maßgeschneiderten Schädelimplantaten, meldete herausfordernde Ergebnisse für das erste Quartal 2025 mit einem Umsatzrückgang von 34,7 % auf 624.910 $ gegenüber 957.447 $ im ersten Quartal 2024. Das Unternehmen verzeichnete einen operativen Verlust von (140.556 $) im Vergleich zu einem Gewinn von 123.599 $ im Vorjahr. Um diese Herausforderungen zu bewältigen, ernannte Kelyniam Alex Rivero zum nationalen Vertriebsleiter und plant, 2025 zehn neue Vertriebspartner hinzuzufügen.
Das Unternehmen gab eine bedeutende dreijährige Vertriebsvereinbarung mit Osteopore Ltd. bekannt, um deren bioresorbierbare Produkte in den USA zu vertreiben, darunter Osteostrip®, Osteoplug® und Osteomesh®. Diese Partnerschaft zusammen mit Finceramica positioniert Kelyniam als führend in der regenerativen Medizin für die Schädelchirurgie, während das Unternehmen weiterhin die Lieferung maßgeschneiderter Implantate innerhalb von 24-48 Stunden gewährleistet.
- New three-year distribution agreement with Osteopore Ltd. to expand product portfolio
- Plans to onboard 10 additional distributors in 2025 to strengthen sales
- Appointment of new National Sales Director to improve sales organization
- Maintains competitive advantage with 24-48 hour custom implant delivery
- Revenue decreased 34.7% to $624,910 in Q1 2025
- Operating loss of $(140,556) compared to profit of $123,599 in Q1 2024
- Gross margin declined 36.6% to $470,940
Q1 2025 Financial Highlights (compared to Q1 2024):
- Total revenue of
$624,910 $957,447 34.7% . - Gross margin of
$470,940 $743,719 36.6% . - Operating loss of
$(140,556) $123,599
"Kelyniam experienced a challenging first quarter due to seasonal variability and the timing of surgical schedules, which delayed revenue recognition," said Ross Bjella, CEO of Kelyniam. "To address these challenges, we strengthened our sales organization by appointing Alex Rivero as National Sales Director and plan to onboard up to 10 additional distributors in 2025. Our commitment to delivering custom implants within 24-48 hours, combined with strategic partnerships, positions us for improved performance."
Strategic Partnerships: Kelyniam has entered a three-year distribution agreement with Osteopore Ltd. (ASX: OSX), a
"Our partnerships with Osteopore and Finceramica position Kelyniam as a leader in regenerative medicine in the
Desiree Webb, Kelyniam's Chief Operating and Revenue Officer said, "Osteopore's products are exceptional additions for surgeons in need of a biomimetic and bioresorbable option for areas where natural, healthy bone growth are desired. Kelyniam is laser focused on providing the best in cranial and craniofacial regenerative options, and we look forward to making great strides with Osteopore in
Osteopore's CEO, Dr. Yujing Lim said, "Kelyniam has demonstrated its ability to manufacture and distribute effectively, as shown by their record performance in 2024. We believe that working directly with Kelyniam allows us to leverage their established access to hospitals and potential customers, thereby accelerating customer access to Osteopore's products.
Kelyniam's complete financial results are available at www.kelyniam.com. The company will discuss these results and strategic initiatives at its Annual Shareholder Meeting on June 23, 2025, at 9:00 AM Central Time.
About Kelyniam Global, Inc.
Kelyniam Global, Inc. designs, manufactures, and distributes custom cranial and craniofacial implants using biocompatible materials. Known for its rapid 24-48 hour delivery, Kelyniam collaborates with surgeons and healthcare providers to improve clinical outcomes. Learn more at www.kelyniam.com.
About Osteopore Ltd.
Osteopore Ltd., based in
About Finceramica Faenza S.p.A.
Finceramica, based in Faenza,
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements, including those regarding future sales, distributor expansion, and the impact of strategic partnerships, involve risks and uncertainties that could cause actual results to differ materially from those projected. Such risks include economic conditions, competitive pressures, regulatory changes, and challenges in executing sales strategies, as detailed in Kelyniam's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Kelyniam undertakes no obligation to update these statements except as required by law.
View original content:https://www.prnewswire.com/news-releases/kelyniam-global-announces-q1-2025-financial-results-and-strategic-partnership-302451739.html
SOURCE Kelyniam Global Inc
FAQ
What caused KLYG's revenue decline in Q1 2025?
What products will KLYG distribute through the Osteopore partnership?
How is KLYG addressing its sales challenges?
What is KLYG's delivery timeframe for custom implants?
When is KLYG's Annual Shareholder Meeting for 2025?
